Previous studies of immunosuppressive therapy in asthma have been uncontrolled and conflicting in their results. Two double-blind controlled cross-over trials using two dosage levels of azathioprine (2 mg/kg and 5 mg/kg for three and four weeks respectively) in a total of 20 patients with chronic severe asthma are described. Both objective and subjective assessments by independent observers indicated no significant change in the groups as a whole. However, in four patients, an improvement was attributed to azathioprine therapy. Two patients in whom sputum production was copious showed marked clinical improvement and reduced sputum volume. In four patients, exacerbations of asthma occurred within two weeks of starting azathioprine and a causal relationship was suspected. No serious depression of circulating white blood cells occurred in any patient.
Previous studies of immunosuppressive therapy in asthma have been uncontrolled and conflicting in their results. Two double-blind controlled cross-over trials using two dosage levels of azathioprine (2 mg/kg and 5 mg/kg for three and four weeks respectively) in a total of 20 patients with chronic severe asthma are described. Both objective and subjective assessments by independent observers indicated no significant change in the groups as a whole. However, in four patients, an improvement was attributed to azathioprine therapy. Two patients in whom sputum production was copious showed marked clinical improvement and reduced sputum volume. In four patients, exacerbations of asthma occurred within two weeks of starting azathioprine and a causal relationship was suspected. No serious depression of circulating white blood cells occurred in any patient.
A minority of patients with asthma develop severe persistent symptoms which are poorly relieved by conventional therapy. Partial relief may be obtained with a high dosage of corticosteroids, but these carry a severe risk of side effects. The reasons for the poor response to treatment are obscure. The majority of these patients appear to have an 'intrinsic', non-allergic form of asthma (i.e., late onset, skin tests negative). However, the similarity of the clinical presentation to that in patients with proven allergic reactions and the presence of eosinophilia suggest that immunological mechanisms are involved.
Immunosuppressive therapy with various agents has been effective in certain diseases in which a disturbance of immunological mechanism has been suspected, e.g., rheumatoid arthritis (Mason et al., 1969 ), Crohn's disease (Brooke, Hoffmann, and Swarbrick, 1969) , and chronic active hepatitis (Mackay, 1968) . There are few reports of trials of immunosuppressive therapy in asthma and none of these has been adequately controlled. Waldbott (1952) , using nitrogen mustard, reported unfavourable results in four cases. Cohen, Petty, Szentivanyi, and Priest (1965) obtained sustained improvement in a case of 'intrinsic' asthma using azathioprine over a period of five months. Kaiser and Beall (1966) obtained no improvement in three patients with chronic bronchial asthma treated with azathioprine in a dosage of 2 mg/kg lCorrespondence to N.G.H., Southampton General Hospital, Southampton for four months. Arkins and Hirsch (1966) found no change in two patients with chronic perennial atopic asthma treated over a two-week period with 6-mercaptopurine. However, in two atopic dogs sensitive to ragweed pollen, Arkins, Gotway, Hogan, and Fink (1969) found that the asthmatic response to inhalation challenge was inhibited during a three-month period of treatment with 6-mercaptopurine. Fazio, Minetto, Sartoris, and Cavallero (1969) reported clinical improvement in 23 out of 25 cases of severe continuous asthma treated with methylhydrazine for between 10 and 30 days; improvement in respiratory function was noted in 16 cases. Nicolaescu, Dragulescu, and Racoveanu (1969) (Nathan, Bieber, Elion, and Hitchings, 1961; Corley, Lessner, and Larsen, 1966; Bach, Dardenne, and Fournier, 1969 Other allergic diseases
No. of first-degree relatives with asthma double-blind and assessments (detailed below) which were made by three observers at the beginning and end of each period included clinical assessment, record card analysis, forced expiratory volume, blood gases, specific airway conductance, and daily sputum weights.
Trial 2 In trial 2, also a double-blind comparison with placebo, a higher dose of azathioprine was employed, 300 mg or 5 mg/kg daily in two divided doses, whichever was the smaller. Each treatment was given for a period of four weeks, the second period following immediately on the first. Assessments (detailed below) were made independently by two observers at the start of the trial and at the end of each period; these included clinical assessment, record card analysis, grading of symptoms, forced expiratory volume and expiratory time. In addition, interim assessments were made.
ASSESSMENT The following assessments were made: Record cards Patients recorded their symptoms twice daily on a record card. The patients entered on the card a number between 1 (normal or no symptoms) and 10 (severe, virtually intolerable) for each of the following symptoms: wheeze, breathlessness, chest tightness, and cough. Sputum was graded from 0 to 5 for each 12-hour period: 3=no sputum, 1 =a few specks only, 2= approximately half an eggcupful, 3=one eggcupful, 4=two eggcupsful, and 5=greater than two eggcupsful. A note was made of the number of asthmatic attacks during the day, the number of times woken by breathlessness during the night, and any other treatment taken. All the patients were experienced in this technique as they were already using it to facilitate routine clinical assessments.
Clinical Assessment was based on history, physical examination, and a scrutiny of record cards (see above). Each observer made independent assessments without the knowledge of the results of objective tests. Each patient was judged at the beginning and end of each period to be better, unchanged or worse in comparison with the preceding period.
Grading of symptoms (trial 2 only) The patient recorded his assessment of wheeze and cough over the four-week period as a whole by making a mark on a 10-cm line labelled 'terrible' at one end and 'perfect' at the other, using one line for each symptom. The distance between the mark and the 'terrible' end of the line was measured (i.e., the lower the score the more severe the symptoms), recorded for each symptom and expressed as a percentage of the length of the line.
The patients also selected for themselves a position on a seven-point scale labelled with categories varying from 'much worse' to 'much better' for the following symptoms: difficulty climbing stairs, disturbance of sleep by dyspnoea at night, and chest tightness in the mornings.
Objective measurements The forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) were measured using a Vitalograph dry spirometer and the specific airways conductance (SGAW) was measured using a volume displacement plethysmograph (Mead, 1960) . Measurements of Pco2 and Po2 were made on capillary blood from the warmed ear using Radiometer micro-electrodes and these were assumed to represent Paco2 and Pao2 respectively. Throughout both periods of trial 1, patients made 24-hour collections of sputum which were weighed. Pulse rate, resting respiratory frequency, and forced expiratory time were also measured.
Interim assessments Patients were assessed twice weekly, most patients being visited in their homes. At each visit, patients were asked to select a position on a five-point scale to indicate the state of their chest symptoms. Peak expiratory flow using a Wright peakflow meter was measured and a sample of blood was taken for haematological examination (see below).
Side-effects and precautions At each assessment, patients were asked whether they had noted any adverse effects which they attributed to the trial treatment. The total white cell count was measured twice weekly. In trial 1, an independent observer was responsible for scrutiny of the results of blood examinations. In trial 2, the results of half of the patients were known to one observer and the remainder to the other, in case the development of serious leucopenia made it necessary for one observer to break the code and modify the dosage. In the event, serious leucopenia did not occur in either trial and all observers remained 'blind' until after calculation of the results.
In trial 2, an attempt was made to quantify symptoms to a greater degree and fewer objective tests were made. RESULTS TRIAL 1 Of the 10 patients taking part two were withdrawn; one developed dyspepsia and nausea on azathioprine and the other developed increased breathlessness requiring other treatment. Eight patients completed the study.
Clinical assessment The results of the observers' independent assessments are shown in Table III Objective criteria Azathioprine induced no significant improvement in spirometric tests, Pao2 or PaCo2 (Table IV) . There was a small improvement in airway conductance in the azathioprine period compared with both control and placebo periods which reached significance at the 5% level in the latter comparison. The mean daily weight of the sputum (Table V) showee.! a fall in two patients (a and d), but there was little change in the remainder. One patient had scanty sputum continuously and one did not collect it satisfactorily. White cell counts There was no significant change in the white cell count in either period.
TRIAL 2 Thirteen patients began trial 2. Four patients were withdrawn during the first period. Patient 1 was on placebo and developed an ulcerative pharyngolaryngitis; three patients (8, 10, and 13) developed an exacerbation of asthma approximately one week after starting azathioprine. The deterioration did not appear to be due to bronchial infection. Results are presented for the nine patients who completed the trial.
Clinical assessment (Table VI) The number of patients assessed as being better, the same or worse was similar in each period, but in both periods the majority were better than in the initial assessment. Record card analysis No significant difference was found between the two periods with respect to any symptom. As it seemed possible that, in those patients receiving azathioprine in the first period, the effects might be carried over into the second period, the mean weekly total symptom scores were analysed for each patient. Patients 3, 4, and 5 showed a fall in symptom score which persisted into the placebo period, when the lowest scores were seen. Although the lowest scores in these patients were seen after azathioprine had been withdrawn, there were already well-marked falls in symptom scores in the third and fourth weeks of treatment. Because a similar fall in symptom score was not seen in any patient receiving azathioprine second, these results suggest that the symptom scores on patients 3, 4, and 5 either improved by chance or that these patients responded differently from others.
Graded symptoms and objective measurements Assessments of wheeze and cough (lines 1 and 2), climbing stairs, morning tightness, night disturbance, and spirometric data demonstrated no significant (P<0 5) improvement in the azathioprine as compared with the placebo period. In some instances there was a significant improvement but this was matched by an equal improvement in the placebo period. Interim assessments, including peak flow rate, also showed no significant difference between the two periods. Patient a A university lecturer aged 33 years had been troubled persistently for two years with shortness of breath, wheezing, irritating cough, and waking with breathlessness, usually four times a night. He produced large quantities of viscid sputum, usually non-purulent. Prednisone dosage was rarely less than 20 mg a day during this period. A particular complaint was that he was unable to lecture comfortably. Two weeks after starting azathioprine he noted improvement in his symptoms, particularly in his ability to speak long sentences without breathlessness. The irritating cough and sputum volume also lessened and the breathless attacks at night were reduced to less than once a night. Improvement continued until two weeks after the end of the azathioprine period, when his symptoms returned and progressed over the next week to the same stage as before the trial. The most striking objective change was in the sputum weight (Table IV) , though the FEV1 improved from 1-19 1. to 2-22 1. and the SGAW from 0-025 1./sec/cm H2O to 0-057 1./sec/cm H20. After this trial he pressed for a resumption of azathioprine; improvement again occurred, varying directly with the dose of azathioprine of between 2 and 5 mg/kg, and this persisted throughout the six-month period of follow-up. Life was much more comfortable and he was able to resume lecturing. He still required corticosteroids, though in a much reduced dosage of 12-5 mg daily.
Patient d This patient, aged 49 years, was similar, his main complaints being wheezing, effort dyspnoea, and nocturnal dyspnoea, but sputum production was even greater than in patient a. He had required more than 20 mg of prednisone a day for two years, on which dose his symptoms were still severe. One week after starting azathioprine he noted improvement, which continued until the end of the trial and persisted for two weeks after stopping azathioprine. The most striking objective finding was a reduction of sputum weight on azathioprine and the Pao2 rose from 63 mm on placebo to 82 mm on azathioprine. Improvement was so marked and deterioration on stopping azathioprine so clear that azathioprine was restarted, again with marked improvement. Over the next six months the dosage was increased and the prednisone dosage reduced. The total white cell count was reduced to 4,000/ mm3 on a temporary dosage of 8 mg/kg azathioprine. His symptoms were less troublesome than before and the prednisone was reduced to 10 mg a day. Of the whole group, the two patients who benefited most were in fact those with the largest sputum production. An uncontrolled observation in another patient with copious sputum suggested that azathioprine was effective in reducing the sputum volume.
The exacerbations of asthma in patients 8, 10, and 13 of trial 2 and in patient g of trial 1, all of whom were withdrawn from the study, are of interest. Two had been comparatively stable for at least six months and two for several years. The episode of worsening began with malaise and a marked increase in wheezing and breathlessness in each case. There was no change in the cough and sputum and no evidence of bronchial infection. Their treatment was changed in that steroids were increased and antibiotics given.
Hence they were withdrawn from the trial. The patients' white cell counts were normal at this time. These exacerbations occurred within one week of starting azathioprine and suggested that azathioprine was responsible, especially as only one exacerbation of asthma occurred in the placebo period and that in a patient subject to more frequent exacerbations than these patients.
The patients in this study were selected on purely clinical grounds and variability of individual responses to immunosuppression may be due to the presence of different aetiological mechanisms.
CONCLUSION
Although we have been unable to demonstrate any significant effect of azathioprine in this group of patients with severe chronic asthma as a whole, the response of some individuals within the group, particularly the two with markedly increased sputum production, suggests that the drug may have a beneficial effect in a minority of such patients. Where symptoms are particularly troublesome and intractable, we believe a careful therapeutic trial of azathioprine is justified. However, there is the possibility that in some patients exacerbation may be precipitated and long-term toxic effects may occur. Further studies are clearly required to determine the place of immunosuppressive therapy in asthma.
